AJHE2404 - CME/CMLE - Clinicopathological features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma-Clinicopathological features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma

Clinicopathological features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma

Pdf Summary

The study explores the relationship between CD30 expression and extranodal natural killer/T-cell lymphoma (ENKTL) prognosis. Positive CD30 expression is associated with better overall survival in ENKTL patients. The study included 82 newly diagnosed ENKTL patients and found that those with high CD30 expression levels (40%) had improved survival compared to those with negative or low expression. CD30 expression was also linked to the Epstein-Barr virus status. The study identified the optimal CD30 expression cutoff point at 40% through analysis and confirmed it as a favorable prognostic factor for ENKTL. Additionally, CD30 expression was a significant factor in survival outcomes for patients with certain clinical characteristics like ECOG performance status and disease stages. This research aims to provide insights into CD30's prognostic value in ENKTL, emphasizing its potential as a biomarker for guiding individualized treatment strategies. Further investigations may help uncover the underlying mechanisms of the association and validate CD30's role in ENKTL prognosis.

Keywords

CD30 expression

extranodal natural killer/T-cell lymphoma

prognosis

overall survival

Epstein-Barr virus

newly diagnosed

survival outcomes

clinical characteristics

ECOG performance status

individualized treatment strategies